BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37802923)

  • 21. Race and sex disparities in the treatment of older patients with T1a renal cell carcinoma: a comorbidity-controlled competing-risks model.
    Patel HD; Kates M; Pierorazio PM; Allaf ME
    Urol Oncol; 2014 Jul; 32(5):576-83. PubMed ID: 24629500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention.
    Patel HD; Riffon MF; Joice GA; Johnson MH; Chang P; Wagner AA; McKiernan JM; Trock BJ; Allaf ME; Pierorazio PM
    J Urol; 2016 Nov; 196(5):1356-1362. PubMed ID: 27140071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Focal therapy for small renal masses : Observation, ablation or surgery].
    Wendler JJ; Friebe B; Baumunk D; Blana A; Franiel T; Ganzer R; Hadaschik B; Henkel T; Köhrmann KU; Köllermann J; Kuru T; Machtens S; Roosen A; Salomon G; Schlemmer HP; Sentker L; Witzsch U; Liehr UB; Ricke J; Schostak M
    Urologe A; 2016 May; 55(5):594-606. PubMed ID: 27119957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes.
    McIntosh AG; Ristau BT; Ruth K; Jennings R; Ross E; Smaldone MC; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG
    Eur Urol; 2018 Aug; 74(2):157-164. PubMed ID: 29625756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis.
    Larcher A; Trudeau V; Sun M; Boehm K; Meskawi M; Tian Z; Fossati N; Dell'Oglio P; Capitanio U; Briganti A; Shariat SF; Montorsi F; Karakiewicz PI
    BJU Int; 2016 Oct; 118(4):541-6. PubMed ID: 26384713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and radiographic characteristics governing the selection of therapy of small renal masses.
    Jackson M; Cusano A; Haddock P; Staff I; Abarzua-Cabezas F; Kesler S; Meraney A; Shichman S
    Can J Urol; 2014 Dec; 21(6):7529-35. PubMed ID: 25483759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Racial Disparities in Active Surveillance for Prostate Cancer.
    Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
    J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Racial/Ethnic and Socioeconomic Disparities in Management of Incident Paroxysmal Atrial Fibrillation.
    Eberly LA; Garg L; Yang L; Markman TM; Nathan AS; Eneanya ND; Dixit S; Marchlinski FE; Groeneveld PW; Frankel DS
    JAMA Netw Open; 2021 Feb; 4(2):e210247. PubMed ID: 33635328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.
    Pierorazio PM; Johnson MH; Ball MW; Gorin MA; Trock BJ; Chang P; Wagner AA; McKiernan JM; Allaf ME
    Eur Urol; 2015 Sep; 68(3):408-15. PubMed ID: 25698065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment.
    Smaldone MC; Churukanti G; Simhan J; Kim SP; Reyes J; Zhu F; Kutikov A; Viterbo R; Chen DY; Greenberg RE; Uzzo RG
    Urology; 2013 Feb; 81(2):269-75. PubMed ID: 23374778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy.
    Wehle MJ; Thiel DD; Petrou SP; Young PR; Frank I; Karsteadt N
    Urology; 2004 Jul; 64(1):49-52. PubMed ID: 15245934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of synchronous and metachronous bilateral small renal masses (< 4 cm): a population-based cohort study.
    Sheikh NA; Khan MH; Pillai S; Lang S; Nabi G
    Int Urol Nephrol; 2018 Apr; 50(4):657-663. PubMed ID: 29427144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial nephrectomy versus ablative therapies for cT1a renal masses: A Systematic Review and meta-analysis.
    Hu X; Shao YX; Wang Y; Yang ZQ; Yang WX; Li X
    Eur J Surg Oncol; 2019 Sep; 45(9):1527-1535. PubMed ID: 31171480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention.
    Kouba E; Smith A; McRackan D; Wallen EM; Pruthi RS
    J Urol; 2007 Feb; 177(2):466-70; discussion 470. PubMed ID: 17222611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry.
    Uzosike AC; Patel HD; Alam R; Schwen ZR; Gupta M; Gorin MA; Johnson MH; Gausepohl H; Riffon MF; Trock BJ; Chang P; Wagner AA; McKiernan JM; Allaf ME; Pierorazio PM
    J Urol; 2018 Mar; 199(3):641-648. PubMed ID: 28951284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.
    Menon AR; Hussein AA; Attwood KM; White T; James G; Xu B; Petroziello M; Roche CL; Kauffman EC
    J Urol; 2021 Aug; 206(2):229-239. PubMed ID: 33780275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis.
    Klatte T; Berni A; Serni S; Campi R
    BJU Int; 2021 Aug; 128(2):131-143. PubMed ID: 34060192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is surveillance of small renal masses safe in the elderly?
    O'Malley RL; Godoy G; Phillips CK; Taneja SS
    BJU Int; 2010 Apr; 105(8):1098-101. PubMed ID: 19849693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with refusing surgery versus planned nonoperative management for rectal cancer.
    Pianka K; Zhao B; Lee K; Liu S; Eisenstein S; Ramamoorthy S; Lopez N
    Surgery; 2022 Nov; 172(5):1309-1314. PubMed ID: 36031444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.